Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Friday. $160.06 million flowed into the stock on the tick-up and $105.21 million flowed out of the stock on the tick-down, for a money net flow of $54.85 million into the stock. Of all companies tracked, Pfizer had the 11th highest net in-flow for the day. Pfizer traded down ($0.21) for the day and closed at $34.98

PFE has been the subject of a number of research reports. JPMorgan Chase & Co. set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Bank of America Corp. reiterated a “buy” rating and set a $28.25 target price (down previously from $38.48) on shares of Pfizer in a report on Tuesday, May 10th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a report on Friday, May 6th. Credit Suisse Group AG increased their target price on Pfizer from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, May 9th. Finally, Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $37.97 target price for the company. in a report on Thursday, July 14th. Ten investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and an average price target of $38.29.

The company has a 50-day moving average of $35.97 and a 200 day moving average of $33.08. The firm has a market cap of $212.18 billion and a P/E ratio of 31.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the previous year, the company posted $0.56 earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be given a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 3.43%. The ex-dividend date is Wednesday, August 3rd.

In other Pfizer news, VP Loretta V. Cangialosi sold 86,000 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $33.97, for a total value of $2,921,420.00. Following the completion of the sale, the vice president now directly owns 271,663 shares of the company’s stock, valued at approximately $9,228,392.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Frank A. Damelio sold 100,000 shares of the company’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the completion of the sale, the executive vice president now directly owns 472,994 shares of the company’s stock, valued at $16,313,563.06. The disclosure for this sale can be found here.

A number of large investors have recently modified their holdings of PFE. PNC Financial Services Group Inc. increased its stake in shares of Pfizer by 16.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,378,870 shares of the biopharmaceutical company’s stock worth $786,951,000 after buying an additional 3,522,873 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Pfizer by 24.7% in the fourth quarter. Jennison Associates LLC now owns 11,912,098 shares of the biopharmaceutical company’s stock worth $384,523,000 after buying an additional 2,361,977 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Pfizer by 4.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 26,881,243 shares of the biopharmaceutical company’s stock worth $867,727,000 after buying an additional 1,246,902 shares during the last quarter. Nicholas Co. Inc. WI increased its stake in shares of Pfizer by 21.5% in the fourth quarter. Nicholas Co. Inc. WI now owns 3,579,485 shares of the biopharmaceutical company’s stock worth $115,545,000 after buying an additional 633,730 shares during the last quarter. Finally, CAM Group Holding A S increased its stake in shares of Pfizer by 111.2% in the fourth quarter. CAM Group Holding A S now owns 1,148,915 shares of the biopharmaceutical company’s stock worth $37,087,000 after buying an additional 605,000 shares during the last quarter.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.